Immuneering (NASDAQ:IMRX) Given “Buy” Rating at Chardan Capital

Immuneering (NASDAQ:IMRX)‘s stock had its “buy” rating restated by analysts at Chardan Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $20.00 target price on the stock. Chardan Capital’s price objective indicates a potential upside of 309.00% from the company’s previous close.

Several other research firms also recently weighed in on IMRX. Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a research note on Friday, March 27th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 target price on shares of Immuneering in a research report on Monday, March 9th. Finally, Wall Street Zen upgraded Immuneering from a “sell” rating to a “hold” rating in a research report on Sunday, April 19th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Immuneering currently has an average rating of “Moderate Buy” and a consensus price target of $16.50.

Immuneering Stock Up 0.4%

IMRX traded up $0.02 during midday trading on Tuesday, hitting $4.89. 696,152 shares of the company traded hands, compared to its average volume of 1,323,706. The firm has a market capitalization of $316.37 million, a PE ratio of -4.18 and a beta of 0.37. The company’s 50-day moving average is $5.34 and its 200 day moving average is $5.69. Immuneering has a 52 week low of $1.40 and a 52 week high of $10.08.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.09. On average, sell-side analysts predict that Immuneering will post -1.39 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Immuneering

Several institutional investors have recently made changes to their positions in IMRX. Jane Street Group LLC purchased a new position in shares of Immuneering during the first quarter valued at $32,000. Geode Capital Management LLC increased its stake in shares of Immuneering by 2.0% during the second quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock valued at $776,000 after buying an additional 4,458 shares during the period. XTX Topco Ltd purchased a new position in Immuneering in the second quarter valued at about $90,000. Bridgeway Capital Management LLC raised its holdings in Immuneering by 57.9% in the second quarter. Bridgeway Capital Management LLC now owns 95,449 shares of the company’s stock worth $322,000 after purchasing an additional 35,000 shares in the last quarter. Finally, Corient Private Wealth LLC bought a new position in Immuneering in the second quarter worth about $215,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.